TME Pharma

The publications contained in this archive section are provided for historical purposes only. The views expressed in the publications are those of their respective authors and do not reflect the views of TME Pharma. TME Pharma disavows any obligation to update or correct the information contained in these publications.

Devarapu SK, Kumar Vr S, Rupanagudi KV, Kulkarni OP, Eulberg D, Klussmann S, Anders HJ.
Dual blockade of the pro-inflammatory chemokine CCL2 and the homeostatic chemokine CXCL12 is as effective as high dose cyclophosphamide in murine proliferative lupus nephritis.
Clin Immunol. 2016.
read abstract on

Menne J, Eulberg D, Beyer D, Baumann M, Saudek F, Valkusz Z, Więcek A, Haller H.
C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria.
Nephrol Dial Transplant. 2016.
read article on

Hoehlig K, Klussmann S.
Spiegelbildliche Nukleinsäuren als pharmakologische Wirkstoffe.
Chemie in unserer Zeit 2015, 49(6), 422-5.
read abstract on

Hoehlig K, Klussmann S.
Molekulare Schere.

Chemie in unserer Zeit
2015, 49(6), 421.
read abstract on

Kalnins A, Thomas MN, Andrassy M, Müller S, Wagner A, Pratschke S, Rentsch M, Klussmann S, Kauke T, Angele MK, Bazhin AV, Fischereder M, Werner J, Guba M, Andrassy J.
Spiegelmer Inhibition of MCP-1/CCR2 - Potential as an Adjunct Immunosuppressive Therapy in Transplantation.
Scand J Immunol. 2015, 82(2), 102.
read abstract on

Brockmann C, Brockmann T, Dege S, Busch C, Kociok N, Vater A, Klussmann S, Strauß O, Joussen AM.
Intravitreal inhibition of complement C5a reduces choroidal neovascularization in mice.
Graefes Arch Clin Exp Ophthalmol. 2015.
read abstract on

Oberthür D, Achenbach J, Gabdulkhakov A, Buchner K, Maasch C, Falke S, Rehders D, Klussmann S, Betzel C.
Crystal structure of a mirror-image L-RNA aptamer (Spiegelmer) in complex with the natural L-protein target CCL2.
Nature Commun. 2015, 6, 6923.
read article on

Yatime L, Maasch C, Hoehlig K, Klussmann S, Andersen GR, Vater A.
Structural basis for the targeting of complement anaphylatoxin C5a using a mixed L-RNA/L-DNA aptamer.
Nature Commun. 2015, 6, 6481.
read article on

Mavroidis M, Davos CH, Psarras S, Varela A, C Athanasiadis N, Katsimpoulas M, Kostavasili I, Maasch C, Vater A, van Tintelen JP, Capetanaki Y.
Complement system modulation as a target for treatment of arrhythmogenic cardiomyopathy.
Basic Res Cardiol. 2015, 110(3), 485.
read abstract on

Haller H, Menne J, Baumann M, Eulberg D.
CCL2 Inhibition with Emapticap Pegol (NOX-E36) in Type 2 Diabetic Patients with Albuminuria.

ISN World Congress of Nephrology
2015, Cape Town

Benedetti E, Duchemin N, Bethge L, Vonhoff S, Klussmann S, Vasseur JJ, Cossy J, Smietana M, Arseniyadis S.
DNA-cellulose: an economical, fully recyclable and highly effective chiral biomaterial for asymmetric catalysis.
Chem. Comm. 2015, 51(28), 6076-9.
read abstract on

Hoehlig K, Bethge L, Klussmann S.
Stereospecificity of Oligonucleotide Interactions Revisited: No Evidence for Heterochiral Hybridization and Ribozyme/DNAzyme Activity.
PLoS One. 2015, 10(2), e0115328.
read abstract on

Hoehlig K, Johnson KW, Pryazhnikov E, Maasch C, Clemens-Smith A, Purschke W, Vauléon S, Buchner K, Jarosch F, Khiroug L, Vater A, Klussmann S.
A Novel CGRP-neutralizing Spiegelmer Attenuates Neurogenic Plasma Protein Extravasation.
Br.J.Pharmacol. 2015.
read abstract on

Vater A, Klussmann S.
Turning mirror-image oligonucleotides into drugs: the evolution of Spiegelmer therapeutics.
Drug Discovery Today. 2015, 20(1), 147-155.
read article on

We use cookies

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (Google Analytics cookies). You can decide for yourself whether you want to accept the cookies. Please note that if you refuse cookies, you may no longer be able to use all of the site's functions.